Posts

Alnylam Cuts Amvuttra Sales Guidance as Second-Line Demand Normalizes, Hitting Stock

on

Roche sees receding biosimilar impact, but Vabysmo slump returns

on

GSK axes key cough drug candidate after mixed Phase 3 data end blockbuster hopes

on

Sangamo puts substantially all assets up for sale in bankruptcy, lines up Lilly and Astellas as buyers

on

Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

on

Lantheus mulls potential $7B sale after Curium takeover offer – Bloomberg

on

Daiichi Sankyo Targets Nearly $15B in Oncology Sales by 2030 via ADC Franchise Expansion

on

Regeneron's Eylea Quarterly Sales Drop Below $1B for First Time in 8 Years Amid Competition and Shift to High-Dose Version

on

No Recent News on Thermo Fisher Scientific Selling Microbiology Business for $1B

on

Sanofi's Dupixent LCM Strategy Gains Prominence Amid Q1 2026 Success and Patent Defense Plans

on

Rare Disease Sales Projected to Exceed $400B by 2032 Despite Challenges, Driven by Small Molecule Resurgence

on

Eli Lilly Beats Sales Forecasts and Targets Major 2026 Growth, Outpacing Novo Nordisk

on

AsedaSciences and GenEvolutioN Announce Sales & Marketing Agreement to Integrate Genotoxicity Screen into 3RnD Platform

on

J&J Targets $100 Billion in 2026 Sales Despite Stelara Patent Cliff

on

Pfizer Exits ViiV Healthcare as Shionogi Doubles Stake in $2.13 Billion Deal

on

WuXi AppTec Sells China-Based Clinical Research Units to Hillhouse Investment Management

on

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

on

WuXi AppTec Sells China-Based Clinical Research Units to Hillhouse Investment Management

on

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

on

Amgen's Repatha Cholesterol-Lowering Shot Poised for Sales Boost After Landmark CV Prevention Trial Success

on